Transforming Infection Diagnostics for better infection & sepsis care.

With faster, more accurate testing.

Presymptom Health is a medtech company developing a portfolio of patented AI based diagnostic blood tests that are both faster and more reliable than those available today.

Accelerate diagnosis. Address antimicrobial resistance.

Addressing two growing global healthcare challenges: early infection diagnosis and antimicrobial resistance, the promise of our technology is to transform patient care pathways. Rapid, reliable information about the presence of infection is not available with current diagnostic techniques. This costs money, time, and resources and leads to loss of life.

Accelerate diagnosis of infection & sepsis

Address antimicrobial resistance

Reduce unnecessary hospital admissions

Precision diagnostics: ruling out infection with 95-99% accuracy

InfectiClear® will be our first product to market – an accurate, reliable blood test that rules out infection faster and more accurately than diagnostic techniques currently available. InfectiClearTM has been selected as one of 8 high impact technologies for the pioneering Innovative Devices Access Pathway programme in the UK.

Our approach is pathogen agnostic; investigating immune system changes that occur in the patient at the onset of infection, providing clinicians with the information they need – within clinical guidelines – to pursue alternative diagnostic investigations once infection is ruled out.

Our products are developed using machine learning with real-world patient data.

5,500

Patients who provided blood samples.

150K

Blood samples used to train & validate our assays

7

Clinical trials underpinning our programmes.

12

Participating Hospitals

Our unique clinical metadata is derived from around 150,000 samples and seven studies, using machine learning to extract insights and develop pioneering assays.

Global Perspective:
What the experts say.

“Presymptom Health’s technology has the potential to improve patient outcomes while being a cost-effective solution for healthcare in the UK.”

– Ron Daniels, CEO, The UK Sepsis Trust

“By 2030, no antibiotic should be prescribed without a test which identifies the pathogen as bacterial.”

– Lord Ara Darzi, Surgeon, Director of the Institute of Global Health Innovation at Imperial College London and Chair of the Fleming Initiative

“Ruling out the presence of infection is as important as antibiotic development to address antimicrobial resistance.”

– Chris Whitty, Chief Medical Officer for England and Chief Medical Adviser to the UK Government

Presymptom Health in the media.

October 24, 2024

How Ploughshare spin-out Presymptom Health is using UK defence AI

The healthcare startup was spun out of the MoD-owned entity with a view to commercialising AI-based infection research.

October 7, 2024

UK defence IP is helping an AI health startup accelerate infection diagnosis

The UK’s Presymptom Health was borne out of an MoD study with a view to commercialising AI-based infection research.

February 14, 2024

Presymptom Health selected to join government pilot

Presymptom Health joins government pilot to get AI-driven infection test into the NHS faster.

Fueling Progress:

Our Investors and Tech Collaborators

Offering expertise and resources, our investors and tech collaborators are critical in the evolution of Presymptom Health.

Our Investors and Grant Funders

Our
Technology Partners